Katti et al., 1992 - Google Patents
A new neutral-lipophilic 99mTc complex with a bis-hydrazide-phosphine (BHP) ligandKatti et al., 1992
View PDF- Document ID
- 7134701400072435200
- Author
- Katti K
- Singh P
- Volkert W
- Ketring A
- Katti K
- Publication year
- Publication venue
- International journal of radiation applications and instrumentation. Part A. Applied radiation and isotopes
External Links
Snippet
A new bis-hydrazide-phosphine (BHP) ligand was synthesized, characterized and complexed with 99m Tc. 99m Tc phenyl-BHP (PBHP) was shown to form a neutral-lipophilic chelate with 99m Tc, in high yields, that is stable over a wide pH range. Results with 99m Tc …
- 230000027455 binding 0 title abstract description 14
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0497—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1231715A (en) | Complexes of technetium-99m with alkylene amine oximes | |
| US5387409A (en) | Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group | |
| US4452774A (en) | Isonitrile radionuclide complexes for labelling and imaging agents | |
| Katti et al. | A new neutral-lipophilic 99mTc complex with a bis-hydrazide-phosphine (BHP) ligand | |
| Berning et al. | 198Au-labeled hydroxymethyl phosphines as models for potential therapeutic pharmaceuticals | |
| Smith et al. | In vitro and in vivo characterization of novel water-soluble dithio-bisphosphine 99mTc complexes | |
| Kothari et al. | Syntheses, in vitro and in vivo characterization of a 99mTc-(I)-tricarbonyl-benzylamino-dihydroxymethyl phosphine (NP2) chelate | |
| US5079346A (en) | Gallium-labelled imaging agents | |
| US5420321A (en) | Tris(isonitrile)copper(i) sulfates for preparing radionuclide complexes | |
| Francesconi et al. | Synthesis, characterization and solid state structure of a neutral gallium (III) amino thiolate complex: a potential radiopharmaceutical for PET imaging | |
| Maresca et al. | Synthesis, characterization, and biodistribution of a Technetium-99m ‘3+ 1’fatty acid derivative. The crystal and molecular structures of a series of oxorhenium model complexes | |
| US4894445A (en) | Metal-isonitrile adducts for preparing radionuclide complexes | |
| WO1989002433A1 (en) | Tris(isonitrile)copper(i) adducts for preparing radionuclide complexes | |
| US5324824A (en) | Metal-isonitrile adducts for preparing radionuclide complexes | |
| US5855867A (en) | Hydroxymethyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and method of making same | |
| CA2022579A1 (en) | Boronic acid adducts of technetium-99m dioxime-imine complexes | |
| EP0138384B1 (en) | Imaging cardiac infarcts with radioactive metals complexed with phosphonate derivatives | |
| Tsotakos et al. | Benzimidazole derivatives as NSO ligands for the fac-[M (CO) 3]+(M= Re, 99mTc) | |
| Singh et al. | Transition metal chemistry of main group hydrazides, part 14: Evaluation of new Tc-99m chelates of thiol functionalized phosphorus hydrazides | |
| Singh et al. | Synthesis, characterization and biodistribution studies of a neutral-lipophilic Tc-99m N3S2 chelate | |
| Brandau et al. | New renal function imaging agents. I. Synthesis and biological characterization of a [99mTc] diaminomercapto (thio) ether (DAMTE) | |
| WO1995005388A1 (en) | AZIDE DERIVATIVES SUITABLE FOR PREPARATION OF 99mTc COMPLEXES FOR IMAGING AND THEIR USE | |
| Guo et al. | Synthesis and biodistribution of 99mTcN-isopentyl xanthate as a potential myocardial perfusion imaging agent | |
| NZ314409A (en) | Preparation of a coordination complex of an isonitrile ligand and a radionuclide (typically technetium (tc)) by replacing copper in a sulphate complex | |
| Easson | Synthesis of tailored ligands for radiopharmaceutical applications |